CERS2

Across TCGA pan-cancer cohorts, CERS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CERS2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CERS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CERS2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, GBM, and CCRCC are the cancer types where CERS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.107	1.000	.010	34	view →
GBM	DFS	Tertile	All	0.292	0.474	.003	21	view →
CCRCC	OS	Median	All	0.652	1.000	.008	13	view →
UCEC	DFS	Quartile	All	0.787	1.000	.015	12	view →
LSCC	OS	Median	All	1.000	0.938	.013	9	view →
LUAD	DFS	Quartile	All	0.727	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CERS2–HNSC (OS)

Open the HNSC breakdown →